Payment overview · 2025
General Payments
$170.84
9 reported records · 8 companies
Healthcare provider profile · identity verified
Ryan D Newell, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, WV · NPI 1174516553
Verified facts
What the public records show
CMS Open Payments records show Ryan D Newell, D.O. received $170.84 in general payments during 2025 across 9 reported records.
Exact Sciences Corporation accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.71 | 23.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.55 | 15.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.40 | 13.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.36 | 11.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.53 | 10.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.00 | 9.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.69 | 8.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.60 | 8.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.84 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.71 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 32 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 19 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 354 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 94 |
| Simvastatin | Simvastatin | 338 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 328 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 289 | 78 |
| Lisinopril | Lisinopril | 283 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 73 |
| Omeprazole | Omeprazole | 246 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 67 |
| Celecoxib | Celecoxib | 219 | 70 |
| Gabapentin | Gabapentin | 213 | 35 |
| Furosemide | Furosemide | 196 | 53 |
| Tramadol Hcl | Tramadol Hcl | 195 | 43 |
| Januvia | Sitagliptin Phosphate | 184 | 54 |
| Montelukast Sodium | Montelukast Sodium | 182 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 46 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 32 |
| Potassium Chloride | Potassium Chloride | 136 | 33 |
| Sertraline Hcl | Sertraline Hcl | 133 | 33 |
| Ozempic | Semaglutide | 127 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 52 |
| Lorazepam | Lorazepam | 119 | 23 |
| Metformin Hcl | Metformin Hcl | 111 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 24 |
| Eliquis | Apixaban | 100 | 26 |
| Metformin Hcl Er | Metformin Hcl | 100 | 27 |
| Xarelto | Rivaroxaban | 96 | 28 |
| Nitroglycerin | Nitroglycerin | 93 | 55 |
| Allopurinol | Allopurinol | 91 | 24 |
| Ezetimibe | Ezetimibe | 91 | 31 |
| Meloxicam | Meloxicam | 89 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 76 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 20 |
| Clonazepam | Clonazepam | 74 | 11 |
| Synthroid | Levothyroxine Sodium | 74 | 18 |
| Alendronate Sodium | Alendronate Sodium | 68 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 23 |
| Donepezil Hcl | Donepezil Hcl | 62 | 20 |
| Glipizide | Glipizide | 62 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 33 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | suppressed |
| Carvedilol | Carvedilol | 54 | 16 |
| Pregabalin | Pregabalin | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 13 |
| Glipizide Er | Glipizide | 52 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 12 |
| Finasteride | Finasteride | 50 | 18 |
| Buspirone Hcl | Buspirone Hcl | 45 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 13 |
| Atenolol | Atenolol | 40 | 12 |
| Cefdinir | Cefdinir | 38 | 34 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Novolog Flexpen | Insulin Aspart | 36 | 12 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Nystatin | Nystatin | 31 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Famotidine | Famotidine | 30 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 25 |
| Ibu | Ibuprofen | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 19 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Fluconazole | Fluconazole | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Klor-Con | Potassium Chloride | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.84 · 9 records | Exact Sciences Corporation | AREXVY, BEXSERO, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 2, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error